Ensysce Biosciences, Inc. also files under LACQ, LACQ); those filings are included.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 7, 2026 | Gower Bob G | Director | Buy(P) | 400K | $0.50 | $198K |
| Apr 23, 2026 | Gower Bob G | Director | Conversion(C) | 254K | — | — |
| Apr 23, 2026 | Gower Bob G | Director | Buy(P) | 509K | $0.48 | $246K |
| Mar 2, 2023 | Gower Bob G | Director | Buy(P) | 90K | $0.49 | $44K |
| Mar 1, 2023 | Gower Bob G | Director | Buy(P) | 270K | $0.48 | $130K |
| Feb 28, 2023 | Gower Bob G | Director | Buy(P) | 109K | $0.49 | $54K |
| Dec 9, 2022 | Gower Bob G | Director | Grant(A) | 714K | — | — |
| Dec 9, 2022 | Gower Bob G | Director | Buy(P) | 357K | $1.40 | $500K |
| Jun 23, 2022 | Levin Adam | Director | Grant(A) | 15K | — | — |
| Jun 23, 2022 | Rosebraugh Curtis | Director | Grant(A) | 20K | — | — |
| Jun 23, 2022 | Gower Bob G | Director, 10% Owner | Grant(A) | 15K | — | — |
| Jun 23, 2022 | Rauch Lee M. | Director | Grant(A) | 15K | — | — |
| Jun 23, 2022 | Martin Steven Robert | Director | Grant(A) | 15K | — | — |
| Jun 23, 2022 | Chang William H | Director, 10% Owner | Grant(A) | 15K | — | — |
| Jun 23, 2022 | Benton Andrew | Director | Grant(A) | 15K | — | — |
| May 26, 2022 | Kirkpatrick Lynn | Chief Executive Officer, Director | Buy(P) | 27K | $0.53 | $14K |
| May 25, 2022 | Kirkpatrick Lynn | Chief Executive Officer, Director | Buy(P) | 70K | $0.49 | $34K |
| Feb 17, 2022 | Kirkpatrick Lynn | Chief Executive Officer, Director | Grant(A) | 200K | — | — |
| Feb 17, 2022 | Kirkpatrick Lynn | Chief Executive Officer, Director | Grant(A) | 200K | — | — |
| Feb 17, 2022 | Birkett Kevin Geoffrey | Chief Commercial Officer | Grant(A) | 50K | — | — |
| Feb 17, 2022 | Humphrey David Carl | Chief Financial Officer | Grant(A) | 80K | — | — |
| Feb 4, 2022 | Benton Andrew | Director | Grant(A) | 20K | — | — |
| Feb 4, 2022 | Chang William H | Director, 10% Owner | Grant(A) | 20K | — | — |
| Feb 4, 2022 | Martin Steven Robert | Director | Grant(A) | 20K | — | — |
| Feb 4, 2022 | Levin Adam | Director | Grant(A) | 20K | — | — |
| Feb 4, 2022 | Rosebraugh Curtis | Director | Grant(A) | 20K | — | — |
| Feb 4, 2022 | Gower Bob G | Director, 10% Owner | Grant(A) | 20K | — | — |
| Feb 4, 2022 | Pestano Linda | Chief Development Officer | Grant(A) | 200K | — | — |
| Feb 4, 2022 | Humphrey David Carl | Chief Financial Officer | Grant(A) | 275K | — | — |
| Jun 30, 2021 | Weil A Lorne | 10% Owner | Grant(A) | 388K | $1.00 | $388K |
| Jun 30, 2021 | Chang William H | Director, 10% Owner | Grant(A) | 353K | — | — |
| Jun 30, 2021 | Humphrey David Carl | Chief Financial Officer | Grant(A) | 50K | — | $0 |
| Jun 30, 2021 | Chang William H | Director, 10% Owner | Grant(A) | 2.2M | — | — |
| Jun 30, 2021 | Birkett Kevin Geoffrey | Chief Commercial Officer | Grant(A) | 20K | — | — |
| Jun 30, 2021 | Birkett Kevin Geoffrey | Chief Commercial Officer | Grant(A) | 329K | — | — |
| Jun 30, 2021 | Schmidt William K | Chief Medical Officer | Grant(A) | 69K | — | — |
| Jun 30, 2021 | Wright Richard Chester | Chief Business Officer | Grant(A) | 66K | — | — |
| Jun 30, 2021 | Wright Richard Chester | Chief Business Officer | Grant(A) | 50K | — | — |
| Jun 30, 2021 | Wright Richard Chester | Chief Business Officer | Grant(A) | 988K | — | — |
| Jun 30, 2021 | Wright Richard Chester | Chief Business Officer | Grant(A) | 263K | — | — |
| Jun 30, 2021 | Wright Richard Chester | Chief Business Officer | Grant(A) | 20K | — | — |
| Jun 30, 2021 | Martin Steven Robert | Director | Grant(A) | 66K | — | — |
| Jun 30, 2021 | Benton Andrew | Director | Grant(A) | 66K | — | — |
| Jun 30, 2021 | Kirkpatrick Lynn | Chief Executive Officer, Director | Grant(A) | 285K | — | — |
| Jun 30, 2021 | Kirkpatrick Lynn | Chief Executive Officer, Director | Grant(A) | 7K | — | — |
| Jun 30, 2021 | Kirkpatrick Lynn | Chief Executive Officer, Director | Grant(A) | 461K | — | — |
| Jun 30, 2021 | Kirkpatrick Lynn | Chief Executive Officer, Director | Grant(A) | 818K | — | — |
| Jun 30, 2021 | Kirkpatrick Lynn | Chief Executive Officer, Director | Grant(A) | 659K | — | — |
| Jun 30, 2021 | Kirkpatrick Lynn | Chief Executive Officer, Director | Grant(A) | 263K | — | — |
| Jun 30, 2021 | Kirkpatrick Lynn | Chief Executive Officer, Director | Grant(A) | 10K | — | — |
| Jun 30, 2021 | Kirkpatrick Lynn | Chief Executive Officer, Director | Grant(A) | 100K | — | — |
| Jun 30, 2021 | Gower Bob G | Director, 10% Owner | Grant(A) | 7.9M | — | — |
| Jun 30, 2021 | Gower Bob G | Director, 10% Owner | Grant(A) | 7K | — | — |
| Jun 30, 2021 | Matthews Lane Capital Partners LLC | 10% Owner | Grant(A) | 1.6M | $1.00 | $1.6M |
| Jun 30, 2021 | Matthews Lane Capital Partners LLC | 10% Owner | Disposed to issuer(D) | 250K | — | $0 |
| Jun 30, 2021 | Matthews Lane Capital Partners LLC | 10% Owner | Grant(A) | 367K | $1.00 | $367K |
| Jun 30, 2021 | Carrera Eric | Insider | Grant(A) | 30K | $1.00 | $30K |
| Jun 30, 2021 | Peng George | Insider | Grant(A) | 15K | $1.00 | $15K |
| Jun 30, 2021 | Weil A Lorne | 10% Owner | Disposed to issuer(D) | 250K | — | $0 |
| Jun 30, 2021 | Weil A Lorne | 10% Owner | Grant(A) | 1.0M | $1.00 | $1.0M |
| Jun 30, 2021 | Weil A Lorne | 10% Owner | Grant(A) | 730K | $1.00 | $730K |
| Jun 19, 2020 | Morgan Stanley | 10% Owner | Sell(S) | 776K | — | — |
| Jan 15, 2018 | Weil A Lorne | Executive Chairman, Director | Other(J) | 132K | — | $0 |
| Jan 15, 2018 | Weil A Lorne | Executive Chairman, Director | Other(J) | 41K | — | $0 |
| Jan 15, 2018 | HG Vora Capital Management, LLC | 10% Owner | Other(J) | 375K | — | $0 |
| Jan 15, 2018 | Peng George | Chief Financial Officer | Other(J) | 13K | — | $0 |
| Jan 15, 2018 | Carrera Eric | Senior Vice President | Other(J) | 8K | — | $0 |
| Jan 15, 2018 | Matthews Lane Capital Partners LLC | Insider | Other(J) | 172K | — | $0 |
| Dec 5, 2017 | Silvers Daniel B. | Chief Executive Officer, Director | Other(J) | 360K | — | $0 |
| Dec 5, 2017 | Weil A Lorne | Executive Chairman, Director | Other(J) | 170K | — | $0 |
| Dec 5, 2017 | Weil A Lorne | Executive Chairman, Director | Other(J) | 187K | — | $0 |
| Dec 5, 2017 | HG Vora Capital Management, LLC | 10% Owner | Other(J) | 719K | — | $0 |
| Dec 5, 2017 | Carrera Eric | Senior Vice President | Other(J) | 1K | — | $0 |
| Dec 5, 2017 | Peng George | Chief Financial Officer | Other(J) | 733 | — | $0 |
| Dec 1, 2017 | HG Vora Capital Management, LLC | 10% Owner | Buy(P) | 1.0M | $10.00 | $10.0M |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: Ensysce Biosciences, Inc., SEC CIK 0001716947. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under ENSC and shows every filing by that issuer (also filed as LACQ, LACQ)).
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-08. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for ENSC